secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001447362-23-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences FY2022 revenue $137M (+46% YoY); guides FY2023 revenue $170-180M
--------------------------------------------------------------------------------

- Full-year 2022 revenue $137.0M, up 46% from $94.1M; test reports 44,419, up 58%.
- Q4 2022 revenue $38.3M (+53% YoY); test reports 12,644 (+53%).
- Net loss $67.1M (incl. $36.3M stock compensation) vs $31.3M loss in 2021.
- Adjusted EBITDA -$42.6M vs -$14.9M; cash and investments $258.6M at year-end.
- FY2023 revenue outlook $170-180M; reaffirms 2025 targets of $255-330M revenue and cash flow positivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736223000036/0001447362-23-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736223000036/cstl-20230228.htm
  HTML page:      https://secwatch.observer/filing/0001447362-23-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer